Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) EPS (Weighted Average and Diluted) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with $0.21 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 156.76% to $0.21 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.96, a 62.06% increase, with the full-year FY2024 number at -$2.34, up 44.81% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.21 for Q3 2025 at Plus Therapeutics, down from $0.69 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.69 in Q2 2025 to a low of -$3.56 in Q2 2022.
  • A 5-year average of -$1.05 and a median of -$0.7 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 1075.28% in 2022, then surged 197.18% in 2025.
  • Plus Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.28 in 2021, then crashed by 742.86% to -$2.36 in 2022, then skyrocketed by 70.34% to -$0.7 in 2023, then grew by 4.29% to -$0.67 in 2024, then soared by 131.34% to $0.21 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's EPS (Weighted Average and Diluted) are $0.21 (Q3 2025), $0.69 (Q2 2025), and -$1.19 (Q1 2025).